18β-glycyrrhetinic acid suppresses gastric cancer by activation of miR-149-3p-Wnt-1 signaling
Metrics: PDF 908 views | HTML 1286 views | ?
Donghui Cao1, Zhifang Jia1, Lili You1, Yanhua Wu1, Zhen Hou2, Yueer Suo2, Houjun Zhang2, Simin Wen1, Tetsuya Tsukamoto3, Masanobu Oshima4, Jing Jiang1, Xueyuan Cao2
1Division of Clinical Research, First Hospital of Jilin University, Changchun, Jilin 130021, China
2Department of Gastric and Colorectal Surgery, First Hospital of Jilin University, Changchun, Jilin 130021, China
3Department of Diagnostic Pathology I, School of Medicine, Fujita Health University, Toyoake, 470-1192, Japan
4Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan
Jing Jiang, email: email@example.com
Xueyuan Cao, email: firstname.lastname@example.org
Keywords: 18β-glycyrrhetinic acid, gastric cancer, COX-2, miR-149-3p, Wnt-1
Received: May 05, 2016 Accepted: September 24, 2016 Published: October 04, 2016
18β-glycyrrhetinic acid (GRA) exerts anti-tumor effects on various types of cancer. In the present study, we found that GRA attenuated the severity of gastritis and suppressed gastric tumorigenesis in transgenic mice. We also discovered that miR-149-3p was downregulated in gastric cancer tissues and cell lines as compared to normal gastric tissues and epithelial cells, but was upregulated by GRA. miR-149-3p expression also correlated negatively with lymphnode metastasis. Our functional assays showed that miR-149-3p overexpression inhibited cell proliferation and cell cycle progression while inducing apoptosis, while inhibition of miR-149-3p had the opposite effects. In addition, we identified Wnt-1 as a direct target of miR-149-3p. These data suggest that GRA inhibits the initiation and progression of gastric tumors by ameliorating the inflammatory microenvironment through downregulation of COX-2 expression and by inhibiting Wnt-1 expression through the upregulation of tumor suppressor miR-149-3p. GRA may thus have the potential to serve as a useful therapeutic agent for the prevention and treatment of gastric cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.